S&P 500   3,858.85 (+0.18%)
DOW   31,216.82 (+0.09%)
QQQ   326.68 (+0.90%)
AAPL   136.56 (+3.43%)
MSFT   225.86 (+0.68%)
FB   272.58 (+1.91%)
GOOGL   1,898.78 (+1.00%)
AMZN   3,326.48 (+1.93%)
TSLA   846.89 (-0.42%)
NVDA   548.30 (+2.56%)
BABA   259.89 (-2.11%)
CGC   33.77 (+0.42%)
GE   11.12 (-2.37%)
MU   83.99 (+0.59%)
AMD   91.81 (+3.45%)
NIO   58.24 (+0.92%)
T   28.94 (-0.07%)
F   11.53 (+6.17%)
ACB   11.15 (-3.38%)
BA   207.26 (-1.98%)
DIS   172.35 (-0.74%)
NFLX   578.45 (-1.35%)
GILD   67.13 (-1.26%)
S&P 500   3,858.85 (+0.18%)
DOW   31,216.82 (+0.09%)
QQQ   326.68 (+0.90%)
AAPL   136.56 (+3.43%)
MSFT   225.86 (+0.68%)
FB   272.58 (+1.91%)
GOOGL   1,898.78 (+1.00%)
AMZN   3,326.48 (+1.93%)
TSLA   846.89 (-0.42%)
NVDA   548.30 (+2.56%)
BABA   259.89 (-2.11%)
CGC   33.77 (+0.42%)
GE   11.12 (-2.37%)
MU   83.99 (+0.59%)
AMD   91.81 (+3.45%)
NIO   58.24 (+0.92%)
T   28.94 (-0.07%)
F   11.53 (+6.17%)
ACB   11.15 (-3.38%)
BA   207.26 (-1.98%)
DIS   172.35 (-0.74%)
NFLX   578.45 (-1.35%)
GILD   67.13 (-1.26%)
S&P 500   3,858.85 (+0.18%)
DOW   31,216.82 (+0.09%)
QQQ   326.68 (+0.90%)
AAPL   136.56 (+3.43%)
MSFT   225.86 (+0.68%)
FB   272.58 (+1.91%)
GOOGL   1,898.78 (+1.00%)
AMZN   3,326.48 (+1.93%)
TSLA   846.89 (-0.42%)
NVDA   548.30 (+2.56%)
BABA   259.89 (-2.11%)
CGC   33.77 (+0.42%)
GE   11.12 (-2.37%)
MU   83.99 (+0.59%)
AMD   91.81 (+3.45%)
NIO   58.24 (+0.92%)
T   28.94 (-0.07%)
F   11.53 (+6.17%)
ACB   11.15 (-3.38%)
BA   207.26 (-1.98%)
DIS   172.35 (-0.74%)
NFLX   578.45 (-1.35%)
GILD   67.13 (-1.26%)
S&P 500   3,858.85 (+0.18%)
DOW   31,216.82 (+0.09%)
QQQ   326.68 (+0.90%)
AAPL   136.56 (+3.43%)
MSFT   225.86 (+0.68%)
FB   272.58 (+1.91%)
GOOGL   1,898.78 (+1.00%)
AMZN   3,326.48 (+1.93%)
TSLA   846.89 (-0.42%)
NVDA   548.30 (+2.56%)
BABA   259.89 (-2.11%)
CGC   33.77 (+0.42%)
GE   11.12 (-2.37%)
MU   83.99 (+0.59%)
AMD   91.81 (+3.45%)
NIO   58.24 (+0.92%)
T   28.94 (-0.07%)
F   11.53 (+6.17%)
ACB   11.15 (-3.38%)
BA   207.26 (-1.98%)
DIS   172.35 (-0.74%)
NFLX   578.45 (-1.35%)
GILD   67.13 (-1.26%)
Log in
ASX:MX1

Micro-X Limited (MX1.AX) Stock Forecast, Price & News

Add
Compare
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Micro-X Limited designs, develops, and manufactures ultra-lightweight carbon nano tube based X-ray products for the healthcare and improvised explosive device imaging security markets in Australia. The company offers Carestream DRX Revolution Nano, an ultra-lightweight digital mobile X-ray system for bedside imaging for use in hospital wards and intensive care units; and Rover, a digital mobile X-Ray unit for deployed military hospitals. It is also developing Mobile Backscatter Imager for stand-off imaging of improvised explosive devices. The company was founded in 2011 and is based in Tonsley, Australia.

MarketRank™

Overall MarketRank™

0.42 out of 5 stars

Analyst Opinion: 0.0Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Stock Exchange ASX
Industry Medical Devices
Sub-IndustryN/A
SectorMedical
Current SymbolASX:MX1
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.micro-x.com
Phone61 8 7099 3966
EmployeesN/A

Debt

Debt-to-Equity Ratio84.34
Current Ratio2.91
Quick Ratio2.69

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$4.25 million
Price / Sales0.00
Cash FlowN/A
Price / Cash FlowN/A
Book ValueA$0.04 per share
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Outstanding SharesN/A
Market CapN/A
Next Earnings DateN/A
OptionableNot Optionable

Receive MX1 News and Ratings via Email

Sign-up to receive the latest news and ratings for MX1 and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Micro-X Limited (MX1.AX) (ASX:MX1) Frequently Asked Questions

What stocks does MarketBeat like better than Micro-X Limited (MX1.AX)?

Wall Street analysts have given Micro-X Limited (MX1.AX) a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Micro-X Limited (MX1.AX) wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Who are some of Micro-X Limited (MX1.AX)'s key competitors?

Some companies that are related to Micro-X Limited (MX1.AX) include Adherium Limited (ADR.AX) (ADR), ADM Tronics Unlimited (ADMT), Allegra Orthopaedics Limited (AMT.AX) (AMT), Analytica Limited (ALT.AX) (ALT), AnteoTech Limited (ADO.AX) (ADO), Atomo Diagnostics Limited (AT1.AX) (AT1), AVITA Medical, Inc. (AVH.AX) (AVH), Azure Healthcare Limited (AZV.AX) (AZV), Cannabix Technologies (BLO), Cochlear (CHEOY), Cochlear (CHEOF), Cochlear Limited (COH.AX) (COH), Cyclopharm Limited (CYC.AX) (CYC), EMvision Medical Devices Limited (EMV.AX) (EMV) and Fisher & Paykel Healthcare Co. Limited (FPH.AX) (FPH).
View all of MX1's competitors.

Who are Micro-X Limited (MX1.AX)'s key executives?

Micro-X Limited (MX1.AX)'s management team includes the following people:
  • Mr. Peter Robin Rowland, MD, CEO & Director
  • Mr. Kingsley Hall BEC, CFO & Company Sec.
  • Mr. Brian Gonzales, Chief Scientist

What is Micro-X Limited (MX1.AX)'s stock symbol?

Micro-X Limited (MX1.AX) trades on the ASX under the ticker symbol "MX1."

How big of a company is Micro-X Limited (MX1.AX)?

Micro-X Limited (MX1.AX) has a market capitalization of $0.00 and generates $4.25 million in revenue each year.

What is Micro-X Limited (MX1.AX)'s official website?

The official website for Micro-X Limited (MX1.AX) is www.micro-x.com.

How can I contact Micro-X Limited (MX1.AX)?

The company can be reached via phone at 61 8 7099 3966.

This page was last updated on 1/21/2021 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.